Rhythm Pharmaceuticals, Inc.
RYTM
Rangering i aksjer
#3015
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aksjekurs
$88.37
Sist synkronisert: 2026-10-19
Markedsverdi
$6.08B
Endring (1 dag)
2.55%
Endring (1 år)
-21.37%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
Antall utestående aksjer for Rhythm Pharmaceuticals, Inc. (RYTM)
Antall utestående aksjer per June 2026: 68.59M
Ifølge Rhythm Pharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 68.59M. Ved slutten av December 2023 hadde selskapet 57.67M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Rhythm Pharmaceuticals, Inc. (RYTM) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 68.59M | 12.46% |
| 2024 | 61.00M | 5.76% |
| 2023 | 57.67M | 10.65% |
| 2022 | 52.12M | 5.08% |
| 2021 | 49.60M | 12.40% |
| 2020 | 44.13M | 21.15% |
| 2019 | 36.42M | 17.48% |
| 2018 | 31.00M | 15.99% |
| 2017 | 26.73M | 59.77% |
| 2016 | 16.73M | 64.07% |
| 2015 | 10.20M | 0.00% |
| 2014 | 10.20M | -79.72% |
| 2013 | 50.27M | 0.00% |
| 2012 | 50.27M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 270.16% |
US
|
|
| 396.00M | 477.32% |
US
|
|
| 478.91M | 598.20% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -9.34% |
NL
|
